News · 26 weeks37-29%
2026-03-012026-08-23
Mix2290d
- Insider9(41%)
- SEC Filings7(32%)
- Offering2(9%)
- Earnings2(9%)
- Leadership1(5%)
- Other1(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.SCHEDULE 13G/A - CODEXIS, INC. (0001200375) (Subject)
- SECSEC Form 10-Q filed by Codexis Inc.10-Q - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Reports Second Quarter 2026 Financial ResultsReports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "I am pleased with t
- PRCodexis Appoints David Butler, PhD, to Strategic Advisory BoardREDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the appointment of David Butler, PhD, to its Strategic Advisory Board (SAB). Dr. Butler will provide technical guidance, industry expertise, and strategic insight to support Codexis’ ongoing growth, innovation and core mission. Concurrently, Carole Cobb will be stepping down from the SAB. "We are excited to have David join our SAB and look forward to the contributions he will make," said Alison Moore, PhD., President and Chief Executive Officer of Codexis. "His deep e
- PRCodexis to Report Second Quarter 2026 Financial Results on August 11REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689
- SECSEC Form 8-K filed by Codexis Inc.8-K - CODEXIS, INC. (0001200375) (Filer)
- SECSEC Form 424B5 filed by Codexis Inc.424B5 - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Announces Pricing of Public Offering of Common StockREDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $1.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $23.1 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a
- SECSEC Form 424B5 filed by Codexis Inc.424B5 - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Announces Proposed Public Offering of Common StockREDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering
- SECSEC Form 8-K filed by Codexis Inc.8-K - CODEXIS, INC. (0001200375) (Filer)
- INSIDERSEC Form 4 filed by Director Parker H Stewart4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Cynthia4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Richards Christos4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith David V4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Singhvi Rahul4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Martinborough Esther4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director Dilly Stephen George4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Director De Vre Raymond4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERDirector De Vre Raymond sold $6,174 worth of shares (2,605 units at $2.37), decreasing direct ownership by 3% to 84,811 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- PRCodexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USAREDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while addressing key industry challenges in scalability and sustainability. At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control
- SECSEC Form 10-Q filed by Codexis Inc.10-Q - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
CDXS FAQ
7 questionsWhat does Codexis Inc. do?
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases...Where does CDXS stock trade?
Codexis Inc. (CDXS) is listed on NASDAQ.What sector and industry is CDXS in?
Codexis Inc. operates in the Industrials sector, Major Chemicals industry.When did Codexis Inc. go public?
Codexis Inc. (CDXS) completed its IPO in 2010.What are analysts saying about CDXS?
Codexis Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Hold on 2024-08-19.What companies are similar to CDXS?
Notable peers in the same industry include LIN (Linde plc), APD (Air Products and Chemicals Inc.), IFF (International Flavors & Fragrances Inc.), DOW (Dow Inc.), LYB (LyondellBasell Industries NV). Compare CDXS side-by-side with any of them on Quantisnow.How can I track CDXS on Quantisnow?
Quantisnow aggregates Codexis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDXS to receive live email and push alerts on every new disclosure.